2-methyl-1-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-1H-benzoimidazole-5-carboxylic acid | 1227244-37-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: 2-methyl-1-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-1H-benzoimidazole-5-carboxylic acid
• 英文别名: 2-Methyl-1-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)benzimidazole-5-carboxylic acid
• CAS: 1227244-37-2
• 化学式: C₂₃H₂₆N₂O₂
• 分子量: 362.472
• InChiKey: SPCMXWYWVDZYHD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.2
• 重原子数：
  27
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  55.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-碘-3-硝基苯甲酸甲酯 在 吡啶 、 palladium on activated charcoal 、 氢气 、 caesium carbonate 、 对甲苯磺酸 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 、 溶剂黄146 、 sodium hydroxide 、 bis(dibenzylideneacetone)-palladium⁽⁰⁾ 作用下， 以 1,4-二氧六环 、 甲醇 、 乙酸乙酯 、 甲苯 为溶剂， 反应 10.66h， 生成 2-methyl-1-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-1H-benzoimidazole-5-carboxylic acid
  参考文献：
  名称：

  RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists

  摘要：

  Treating insulin resistance and type 2 diabetes in rodents, currently known retinoid X receptor (RXR) agonists induce significant adverse effects. Here we introduce a novel RXR partial agonist CBt-PMN (11b), which shows a potent glucose-lowering effect and improvements of insulin secretion and glucose tolerance without the serious adverse effects caused by RXR full agonists. We suggest that RXR partial agonists may be a new class of antitype 2 diabetes drug candidates.

  DOI：

  10.1021/ml300055n

文献信息

• RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists
  作者：Hiroki Kakuta、Nobumasa Yakushiji、Ryosuke Shinozaki、Fuminori Ohsawa、Shoya Yamada、Yui Ohta、Kohei Kawata、Mariko Nakayama、Manabu Hagaya、Chisa Fujiwara、Makoto Makishima、Shigeyuki Uno、Akihiro Tai、Ami Maehara、Masaru Nakayama、Toshitaka Oohashi、Hiroyuki Yasui、Yutaka Yoshikawa

  DOI：10.1021/ml300055n

  日期：2012.5.10

  Treating insulin resistance and type 2 diabetes in rodents, currently known retinoid X receptor (RXR) agonists induce significant adverse effects. Here we introduce a novel RXR partial agonist CBt-PMN (11b), which shows a potent glucose-lowering effect and improvements of insulin secretion and glucose tolerance without the serious adverse effects caused by RXR full agonists. We suggest that RXR partial agonists may be a new class of antitype 2 diabetes drug candidates.